Doxorubicin: the good, the bad and the ugly effect.
By C. Carvalho, Renato X Santos, S. Cardoso, S. Correia, P. Oliveira, Maria S. Santos, P. Moreira. Current Medicinal Chemistry, 2009
1,412 citations recorded by the source corpus.
Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/01f446f7f87bc9a0a50586876340a9473b7232c8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Doxorubicin pathways: pharmacodynamics and adverse effects (2011, background): “A B C B 1 rs 35 65 79 60 L eu 66 2A rg G In cr ea se d re si st an ce 17 35 25 37 b [4 6]”
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems (2013, background): “Other side effects of extravasation include cellulitis, thrombophlebitis and joint movement limitation as a result of painful induration (pathological hardening of tissue).([7])”